Journals / Ulusal Romatoloji Dergisi / 2021 / Cilt: 13 - Sayı: 2

Fetuin-A ve psöriyatik artrit hastalık aktivitesi ile ilişkisi

Pages
47–53
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Fetuin-A concentrations were significantly lower in the patients than in controls (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Psoriatic arthritis (PsA) is one of the spondyloarthropathies associated with psoriasis.
📊
Key Findings & Data:Recent data suggest an increased prevalence of cardiovascular disease in patients with PsA, similar to that observed in psoriasis.
💡
Conclusion & Impact:Fetuin-A concentrations were significantly lower in the patients than in controls (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Psoriatic arthritis (PsA) is one of the spondyloarthropathies associated with psoriasis. Recent data suggest an increased prevalence of cardiovascular disease in patients with PsA, similar to that observed in psoriasis. Fetuin-A is a novel biomarker related to vascular calcification and atherosclerosis. In this study, we aimed to investigate the association between fetuin-A concentrations and PsA-related parameters. Methods: Ninety-seven non-diabetic PsA patients who fulfilled the CASPAR criteria and 57 age- and sex-matched healthy controls were included. Disease activity was assessed by using CPDAI, BASDAI, DAS28-CRP and PASI. Serum lipids, high-sensitivity C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR), and fetuin-A were studied. Results: There were 97 PsA patients [48 (min-max: 25-65) years, 32M/65F] and 57 healthy subjects [43 (min-max: 31-57) years, 24M/33F]. Disease duration of the PsA patients was 4 (min-max: 0-43) years. Distributions of age, sex, and body mass index were similar between the groups. Fetuin-A concentrations were significantly lower in the patients than in controls (p

Özet

Amaç: Psöriyatik artrit (PsA), spondiloartropati grubu hastalıklar içerisinde yer alan psöriyazis ile ilişkili bir hastalıktır. Psöriyaziste tanımlanan kardiyovasküler hastalık sıklığının artışının aynı zamanda PsA için de geçerli olduğu bilinmektedir. Fetuin-A, vasküler kalsifikasyon ve aterosklerozla ilişkisi gösterilmiş olan yeni bir biyobelirteçtir. Bu çalışmada PsA’da fetuin-A seviyelerinin ve PsA ilişkili parametreler ile olan ilişkisinin değerlendirilmesi amaçlandı. Yöntem: CASPAR kriterlerine göre tanı almış 97 diyabetik olmayan PsA hastası ve bu gruba yaş ve cinsiyet olarak uyumlu 57 sağlıklı kontrol çalışmaya alındı. Hastalık aktivitesini değerlendirmek için CPDAI, BASDAI, DAS28-CRP ve PASI skorları kullanıldı. Serum lipidleri, yüksek duyarlı C-reaktif protein (hsCRP), eritrosit sedimentasyon hızı (ESH) ve fetuin-A çalışıldı. Bulgular: Çalışmada 97 PsA [48 (min-max: 25-65) yıl, 32E/65K] ve 57 sağlıklı kontrol [43 (min-max: 31-57) yıl, 24E/33K] yer almaktaydı. Hastalık süresi 4 (min-max: 0-43) yıldı. Yaş, cinsiyet dağılımı ve vücut kitle indeksi gruplar arasında benzerdi. Serum fetuin-A seviyeleri hasta grubunda sağlıklı kontrollere göre anlamlı olarak daha düşüktü (p

🔖

Cite This Article

SARI, İ., GÜNAY, N., KOZACI, L. D., KESER, M., ÖZTÜRK, S., ÇETİN, P., ÖNEN, F., GÜLLE, S. (2022). Fetuin-A ve psöriyatik artrit hastalık aktivitesi ile ilişkisi. Ulusal Romatoloji Dergisi, Cilt: 13 - Sayı: 2, 47–53. https://ajindex.com/articles/643887

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Gupta S, Syrimi Z, Hughes DM, Zhao SS. Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int 2021;41:275-84
  2. Jirak P, Stechemesser L, Moré E, et al. Clinical implications of fetuin-A. Adv Clin Chem 2019;89:79-130
  3. Clemente A, Traghella I, Mazzone A, Sbrana S, Vassalle C. Vascular and valvular calcification biomarkers. Adv Clin Chem 2020;95:73-103
  4. Sari I, Kebapcilar L, Taylan A, et al. Fetuin-A and interleukin-18 levels in ankylosing spondylitis. Int J Rheum Dis 2010;13:75-81
  5. Sari I, Yuksel A, Kozaci D, et al. The effect of regular colchicine treatment on biomarkers related with vascular injury in newly diagnosed patients with familial Mediterranean fever. Inflammation 2012;35:1191-7
  6. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988;332:83-5
  7. Taylor W, Gladman D, Helliwell P, et al; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73
  8. Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60
  9. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91
  10. Leung YY, Orbai AM, de Wit M, et al; Remission/Flare in PsA Study Group. Comparing the patient-reported physical function outcome measures in a real-life ınternational cohort of patients with psoriatic arthritis. Arthritis Care Res (Hoboken) 2021;73:593-602
  11. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5
  12. Duruöz MT, Gezer HH, Nas K, et al. The impact of fatigue on patients with psoriatic arthritis: a multi-center study of the TLARnetwork. Rheumatol Int 2020;40:1803-15
  13. Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network metaanalysis. Cochrane Database Syst Rev 2020;1:CD011535. d